Clean Science & Technology Enters Strategic Collaboration with Switzerland’s Geneus Chem AG to Expand Specialty Chemicals Portfolio

What Happened ?

key details

Strategic Collaboration:

• Clean-Fino Chem Limited has entered into a long-term manufacturing and supply agreement with Geneus Chem AG.
• The subsidiary will manufacture advanced grades of HALS products.
• Manufacturing will be undertaken in India.
• Products will be marketed in both domestic and international markets.
• The arrangement supports expansion of Clean Science’s specialty chemicals portfolio. 

Note:

• The collaboration forms part of the company’s long-term specialty chemicals growth strategy.

Equity Acquisition Structure:

• Geneus Chem AG will issue share warrants to Clean-Fino Chem.
• No upfront consideration is payable for the warrants.
• Warrants are exercisable within four years of issuance.
• Upon exercise, the subsidiary will acquire 25% of Geneus Chem AG on a fully diluted basis.
• A nominal price per share will be payable only at the time of exercising the warrants. 

Note:

• The proposed acquisition is not a related-party transaction, and neither the promoters nor promoter group have any interest in Geneus Chem AG.

About Geneus Chem AG:

• Incorporated in Switzerland in 2022.
• Operates in research, development, manufacturing, trading, export and consulting of specialty chemical products.
• Focuses on advanced grades of HALS products.
• Currently operates as a start-up and is not at a significant revenue scale.  

Note:

• Geneus Chem is an early-stage specialty chemicals company with technology-focused operations.

Key Commercial Terms:

• Long-term manufacturing and supply collaboration.
• Worldwide exclusive manufacturing arrangement for advanced HALS products.
• Pricing will be determined through an agreed pricing formula.
• Agreement includes minimum offtake commitments, confidentiality, intellectual property protection, product specifications, non-compete obligations, warranties, indemnities and dispute resolution provisions.  

Note:

• The company has not disclosed commercial pricing or expected revenue from the collaboration.

Risk Analysis

Summary:

• The collaboration provides strategic growth opportunities, but commercial benefits will depend on successful product commercialization, manufacturing execution and future exercise of the equity warrants.

Key Risks:

• Geneus Chem is an early-stage company with limited operating scale.
• Financial benefits from the collaboration have not been quantified.
• Equity acquisition remains contingent upon future warrant exercise.
• Commercial success depends on market demand for advanced HALS products.

Worst Case:

• If commercialization or market adoption of advanced HALS products is weaker than expected, the collaboration may generate lower-than-anticipated strategic or financial benefits, while the warrant option may not create meaningful shareholder value.

Risk Level: Medium

Company Commentary

• The collaboration supports Clean Science’s specialty chemicals growth strategy.
• Clean-Fino Chem will manufacture advanced HALS products on a worldwide exclusive basis.
• Geneus Chem AG has agreed to issue share warrants to the subsidiary.
• The subsidiary may acquire a 25% fully diluted equity stake upon exercising the warrants.
• No regulatory approvals are required for the proposed acquisition.
• The transaction is not a related-party transaction.